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This  study  investigated  the  transmission  of  foot-and-mouth  disease  virus  (FMDV)  from  experimentally
infected  Indian  buffalo  to in-contact  naïve  and  vaccinated  cattle  and buffalo.  In each  of  six rooms,  two
donor  buffalo  that had  been  inoculated  with  FMDV  were  housed  for  ﬁve  days  with  four recipient  animals,
comprising  one  vaccinated  buffalo,  one  vaccinated  calf,  one  unvaccinated  buffalo  and one  unvaccinated
calf.  Vaccination  was  carried  out with  current  Indian  vaccine  strain  (O/IND/R2/75)  and challenged  on 28
days post-vaccination  with  an  antigenically  similar  strain  (O/HAS/34/05).  All  12 donor  buffalo  and  the
six  unvaccinated  cattle  and  six  unvaccinated  calves  developed  clinical  signs  of foot-and-mouth  diseasendian buffalo
ransmission
attle
MD  vaccination in buffalo
(FMD).  In contrast,  all  six  vaccinated  cattle  (100%)  and  four  out  of  six  vaccinated  buffalo  (66.6%)  were
protected  from  disease  but all  became  infected  with  FMDV.  This  conﬁrms  that  buffalo  have  the  potential
to  spread  FMD  by  direct  contact  and that  vaccination  can  block  this  spread.  The numbers  of  animals  in
the  study  were  too small  to determine  if the  differences  in  clinical  protection  afforded  by vaccination  of
cattle and  buffalo  are  signiﬁcant  and  warrant  a different  dose  regime.
Crown Copyright  © 2014  Published  by  Elsevier  Ltd. This  is  an  open  access  article  under  the CC. Introduction
Foot-and-mouth disease (FMD) is a highly contagious disease
f livestock and a major threat to trade and commodity markets
orldwide [1]. FMD  is endemic in India with serotypes O, A and
sia 1 virus in circulation and outbreaks are recorded throughout
he year [2]. India has the world’s largest cattle and buffalo popu-
ation and the 105 million buffalo constitute 57.3% of the world
opulation according to the 2007 census. Indian (Asian) buffalo
Bubalus bubalis) are reared for milk, meat and draft purposes and
hereby play an important role in the Indian economy. Buffalo con-
ributed more than half (53.4%) of the total milk production in India
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during 2010–2011. In India, a mixed farming of cattle and buffalo
is commonly practiced. The role of Indian buffalo in FMD  epidemi-
ology, disease transmission and immune response to vaccination
has been poorly studied. Transmission of FMD  virus from infected
cattle to naïve buffalo and further transmission of virus from buf-
falo to naïve goats were reported previously [3]. Transmission of
FMD  virus from affected cattle and pigs to naïve buffalo as a result
of close contact has also been cited in the literature [4].
In a sub-clinical episode of FMD, introduction of Indian buf-
falo into a cattle herd was  postulated as the probable cause of an
outbreak [5]. African buffalo (Syncerus caffer) are known to be sus-
ceptible to FMDV, to carry virus for long periods without showing
clinical signs, and to be efﬁcient maintenance hosts of the Southern
African Territories (SAT) type viruses [6]. African buffalo can carry
the virus for a period of 5 years, and isolated herds up to 24 years,
although the persistence in individual buffalo is probably not life-
long [7]. Transmission of SAT-type virus from persistently infected
African buffalo to cattle under experimental and natural conditions
has been demonstrated [8] and possibly occurs via sexual contact
[9]. Findings for African buffalo may not hold good for Asian buffalo
since the two  species are distinct, and their roles in FMD  epidemi-
ology probably differ. In our earlier study [10], a buffalo infected
icle under the CC BY-NC-ND license
5  Vacci
v
a
f
t
p
m
b
e
d
c
c
2
2
a
p
o
O
l
i
O
l
S
2
t
e
g
T
F
c
c
u
w
l
s
g
T
i
2
c
o
w
b
b
N
n
r
a
p
b
2
(
M
(126 M. Madhanmohan et al. /
ia the dental pad transmitted infection to naïve cattle and buffalo
fter 24 h direct contact. Considering the large population of buf-
alo in India, the practice of mixed farming of buffalo and cattle and
he inclusion of buffalo in the current national vaccination control
rogram along with cattle, we investigated the possibility of trans-
ission of FMDV from experimentally tongue inoculated Indian
uffalo to in-contact naïve and vaccinated buffalo and cattle. The
fﬁcacy of FMD  vaccine in buffalo was also studied by simulating a
irect contact challenge experiment as knowledge of vaccine efﬁ-
acy is limited in buffalo and assumptions have been made from
attle studies.
. Materials and methods
.1. Cell lines and viruses
Baby Hamster kidney 21 (BHK-21), primary calf thyroid (CTY)
nd the Instituto Biologico Renale Swine-2 (IBRS2) cells were
rovided by the tissue culture laboratory, Research and Devel-
pment Centre, Indian Immunologicals Limited (IIL), Hyderabad.
/IND/R2/75 vaccine strain was received from the virus seed
aboratory, IIL, Hyderabad. O/HAS/34/05 virus was used for exper-
mental infection of buffalo. O/HAS/34/05 virus is homologous to
/IND/R2/75 (r1 value > 1.00) [11]; and was isolated from epithe-
ial tissue of a suspected FMD  case in a non-vaccinated buffalo from
irsa District, Haryana State.
.2. Challenge virus preparation
Challenge virus O/HAS/34/05 was prepared by passaging in the
ongues of buffalo calves as described for cattle by Nagendrakumar
t al. [12]. Brieﬂy, one buffalo calf was inoculated intradermolin-
ually with BHK 21 monolayer adapted O/HAS/34/05 virus (105
CID50). The tongue epithelium was collected 48 h post inoculation.
or a second passage, epithelial tissue was collected from vesi-
les and after trituration in 0.04 M phosphate buffer followed by
entrifugation at 3000 rpm; the clear supernatant was used to inoc-
late (intradermolingually) the 2nd buffalo. The same procedure
as followed for third buffalo passage. Then the tongue epithe-
ium was collected from third passage buffalo and 20% W/V  virus
uspension was prepared. To make the glycerol stock 50% of sterile
lycerol was added to the virus suspension and stored at −20 ◦C.
he virus was then titrated in buffalo calves to establish the buffalo
nfective dose 50 values (BID50).
.3. Experimental animals
Murrah male buffalo calves (n = 24; 6–12 months of age) and
rossbred male cattle calves (n = 12; 6–12 months of age) were
btained from the holding farm of IIL, Hyderabad. These animals
ere reared in the farm from one month of age and were screened
y 3 rounds of testing for FMDV-non-structural protein (NSP) anti-
odies using PrioCHECK® FMDV NS kit (Prionics Lelystad B.V., The
etherlands) and structural antibodies [13]. All the animals were
egative against both NSP and structural antibodies in all the three
ounds of testing. In addition, the animals were tested for the
bsence of virus in the oesophago-pharyngeal ﬂuids (Probang sam-
les) by inoculation of primary bovine thyroid cells [14] followed
y antigen ELISA [15] and RT-PCR [16].
.4. Vaccines, vaccination and experimental designMonovalent FMD  vaccine incorporating O/IND/R2/75
7 g/dose) FMDV inactivated antigen was formulated with
ontanide ISA 206 (Seppic, France) as a water-in-oil-in-water
W/O/W) emulsion. One group of buffalo calves (GrI; n = 6) and ane 32 (2014) 5125–5130
second group of cattle calves (GrII; n = 6) were administered with
2.0 ml  of formulated vaccine by intra-muscular route whereas a
third and a fourth group of buffalo (GrIII; n = 6) and cattle (GrIV;
n = 6) calves remained unvaccinated. Donor buffalo (n = 12) were
inoculated with 105 BID50 of buffalo passaged O/HAS/34/05 FMDV
by the intradermolingual route at 24 h before contact challenge.
At 28 days post-vaccination, one animal from each group (GrI, II,
III and IV) was  housed for 5 days in an individual room along with
two donor buffalo that were inoculated with FMDV 24 h prior to
introduction. After 5 days of contact challenge, the vaccinated and
non-vaccinated animals were separated from the donors. These
animals were rehoused with their original groups (Fig. 1). Clinical
signs and rectal temperatures were monitored for 15 days post
challenge. Experiments were conducted in a bio-secure animal
isolation unit at IIL.
2.5. Sample collection and processing
Clotted blood for serology to detect antibodies to both structural
and non-structural proteins was collected from in-contact vacci-
nated and non-vaccinated cattle and buffalo on 0, 7, 14, 21 and 28
days post-vaccination and on 9, 14, 19, 25, 32 and 39 days post
exposure. The sera were separated, inactivated at 56 ◦C for 30 min
and stored at −20 ◦C until further use.
2.6. Virus neutralizing antibody test (VNT)
Titres of neutralising antibodies against FMDV O/IND/R2/75
virus were measured by micro-neutralization assay as described
in the OIE Manual of Diagnostic Tests and vaccines [13].
2.7. Non-structural protein antibodies
Antibodies to FMDV NSP 3ABC were tested using PrioCHECK®
FMDV NS kit (Prionics Lelystad B.V., The Netherlands) [17].
2.8. Statistical analysis
A linear mixed model was  used to compare neutralising anti-
body titres, with log10 titre as the response variable and time post
challenge (as a factor), species and vaccination status as ﬁxed effects
and animal as a random effect. Model selection proceeded by step-
wise deletion of non-signiﬁcant terms (as judged by the Akaike
information criterion (AIC)) starting from a model including time
post challenge, species and vaccination status together with pair-
wise interactions between each variable.
Similarly, a linear mixed model was used to compare NSP anti-
body responses, with percentage inhibition as the response variable
and time post challenge (as a factor), species and vaccination
status as ﬁxed effects and animal as a random effect. Model selec-
tion proceeded by stepwise deletion of non-signiﬁcant terms (as
judged by the AIC) starting from a model including time post chal-
lenge, species and vaccination status together with an interaction
between species and vaccination status.
Correlation between pre-challenge serum neutralising antibody
titres (i.e. those on day 0 post challenge) and post-challenge NSP
antibody responses (on day 32 and 39 days post challenge) were
assessed for vaccinated buffalo and cattle using Spearman’s rank
correlation coefﬁcient. Correlations between serum neutralising
antibody titres and NSP antibody responses at each time point, post
challenge, were also examined using Spearman’s rank correlation
coefﬁcient for unvaccinated and vaccinated cattle and buffalo.
All statistical analyses were implemented in R [18].
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. Results
.1. Clinical ﬁndings
All twelve of the needle challenged donor buffalo showed
ongue and foot lesions as expected. All the vaccinated cattle (6/6)
nd four vaccinated buffalo (4/6) were protected from clinical dis-
ase after 5 days direct contact challenge with these clinically
nfected donor buffalo. This difference in protection (6/6 in cat-
le vs 4/6 in buffalo) is not statistically signiﬁcant (Fisher exact
est: P = 0.45). Out of the two unprotected vaccinated buffalo, one
able 1
MD  clinical signs in in-contact vaccinated and non-vaccinated buffalo and cattle.
Groups Animal ID
1 2 3 4 5 6 7
Vaccinated
buffalo
B-45531
B-45770
B-45781 
B-45575 
B-45815
B-45666
Vaccinated
cattle
C-46124
C-46443
C-46512
C-46341
C-46374
C-46534
Non-vaccinated
buffalo
B-0037 
B-0043 
B-0035 
B-0040 
B-45611 T
B-45633 4
Non-vaccinated
cattle
C-0007 
C-0004 
C-0015 
C-0028 
C-6799 T
C-0021 
—number of foot revealed lesion, TL—tongue lesion, DL—dental pad lesion.d buffalo calves before and after challenge. Solid black lines represent vaccinated
 animals.
showed foot lesions at 10 days post-challenge (dpc) whereas the
other one showed foot lesions only in one foot starting from 12
dpc (Table 1). The lesions observed were smaller in size in com-
parison to those seen in the non-vaccinated infected animals. No
tongue lesions were observed in these two unprotected vacci-
nated animals. Foot lesions in two of the non-vaccinated buffalo
were observed at 7 dpc, whereas foot lesions in the other four
non-vaccinated buffalo were observed at 11 dpc. Only one non-
vaccinated buffalo developed a tongue lesion, which was observed
at 7 dpc. Five non-vaccinated cattle showed foot lesions at 10
dpc and one showed a foot lesion at 11 dpc. Four of these six
Days post challenge
 8 9 10 11 12 13 14 15
3+ 3+ 4+ 4+ 4+ 4+
1+ 1+ 1+ 1+
3+ 3+ 3+ 3+ 3+
4+ 4+ 4+ 4+ 4+
1+ 1+ 1+ 1+ 1+
4+ 4+ 4+ 4+ 4+
L,4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+
+ 4+ 4+ 4+ 4+ 4+ 4+ 4+ 4+
DL,TL,4+ 4+ 4+ 4+ 4+ 4+
TL,1+ 3+ 3+ 3+ 3+ 3+
3+ 3+ 3+ 3+ 3+
TL, 2+ 3+ 3+ 3+ 3+ 3+
L 2+ 4+ 4+ 4+ 4+ 4+
DL,2+ 3+ 3+ 3+ 3+ 3+
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nprotected cattle showed tongue or dental pad lesions at 10 dpc,
ne showed at 7 dpc and the 6th one did not show any tongue or
ental pad lesion. Pyrexia (≥39.0 ◦C to 40.2 ◦C) was recorded at the
ame time as the appearance of vesicles, but was less evident in the
accinated unprotected animals in comparison to the unprotected
on-vaccinated animals.
.2. Neutralising antibody response
A neutralizing antibody titre to FMDV O/IND/R2/75 was
etected as early as 14 dpv and peak antibody titres were obtained
t 28 dpv in vaccinated buffalo and cattle. The mean antibody titre
n vaccinated buffalo and cattle were 101.2 (95% conﬁdence interval
CI): 100.8–101.7) and 101.5 (95% CI: 101.2–101.8), respectively, at the
ime of exposure. Two vaccinated buffalo that showed clinical signs
ad low serum neutralizing antibody titres (100.9; 101.1) whereas
 third vaccinated buffalo with low neutralizing antibodies (101.1)
t the time of exposure was protected.
Following the challenge exposure, the serum neutralising anti-
ody titres were observed in the range of 101.2 to 101.8 up to
2–39 days post challenge in vaccinated buffalo and cattle (Fig. 2).
n non-vaccinated control buffalo and cattle a rapid seroconver-
ion was evident following exposure to challenge and the antibody
itres (101.0 to 101.4) were detected up to 32–39 dpc (Fig. 2). Both
accinated buffalo and cattle had signiﬁcantly higher neutralising
ntibody titres than non-vaccinated control buffalo and cattle at all
ime points post exposure, but there was no signiﬁcant difference
n serum neutralising antibody titres between vaccinated buffalo
nd cattle at any time point post exposure.
.3. NSP antibody response
NSP antibodies appeared at 9 dpc in three non-vaccinated buf-
alo and four non-vaccinated cattle, at 14 dpc in two non-vaccinated
uffalo and two non-vaccinated cattle and at 19 dpc in one non-
accinated buffalo. NSP antibodies were detected at 14 dpc in three
accinated buffalo and two vaccinated cattle while two vaccinated
uffalo and one vaccinated cattle showed NSP antibodies at 32
pc. One vaccinated buffalo and two vaccinated cattle were not
ositive for NSP antibodies. Virus replication occurred earlier in
on-vaccinated control animals than in the vaccinated animals as
as evident from antibody responses against NSP (Fig. 3).
NSP antibody responses were signiﬁcantly lower in vaccinated
attle compared with unvaccinated cattle and unvaccinated buf-
alo, but not signiﬁcantly different when compared with vaccinated
uffalo. Responses did not vary signiﬁcantly amongst any of the
ther groups (i.e. unvaccinated cattle, unvaccinated buffalo and
accinated buffalo).
.4. Correlation between neutralising and NSP antibody
esponses
There was no signiﬁcant correlation between pre-challenge
erum neutralising antibody titres and post-challenge NSP anti-
ody responses (at either 32 or 39 days post challenge) in
accinated buffalo or cattle. Furthermore, there was no signiﬁcant
orrelation between neutralising antibody titres and NSP antibody
esponses at any time point post exposure for vaccinated or unvac-
inated cattle or buffalo.
. DiscussionIndia has the world’s largest buffalo population and mixed farm-
ng of cattle and buffalo is practiced by farmers. The current FMD
ontrol programme in India mainly involves mass vaccination of
attle and buffalo. However, the efﬁcacy of FMD vaccination ofne 32 (2014) 5125–5130
buffalo is poorly understood and assumptions have been made
by extrapolation from cattle studies. Although, some studies have
investigated the transmission of FMDV from infected buffalo to
naïve buffalo and cattle [3–5], no detailed study has been made
until now to ﬁnd out the efﬁcacy of FMD  vaccines in buffalo, in
particular to investigate the ability of vaccine to block the trans-
mission of FMDV from in-contact infected buffalo to vaccinated
buffalo and cattle. Therefore, this study was designed to investi-
gate the efﬁcacy of current Indian FMD  vaccine (O/IND/R2/75) in
buffalo and its ability to prevent the disease transmission from in-
contact infected buffalo that were challenged with a homologous
(r1 value > 1.00) virulent strain (O/HAS/34/05). Both the vaccine
and challenge viruses belong to the Middle East-South Asia (ME-
SA) topotype. Simultaneously, we  compared the transmission of
disease from in-contact infected buffalo to vaccinated cattle.
Intradermolingual inoculation of FMDV resulted in generalized
disease in all the donor buffalo. The donor buffalo showed both
tongue and foot lesions. These results differ from the observa-
tions of Maddur et al. [19], in which the reaction of buffalo to
experimental infection was  mild. It may  be signiﬁcant that the
virus used in that experiment was  of bovine origin, without adap-
tation to buffalo. However, in the present study, buffalo origin
virus, further adapted by three passages in buffalo was  used which
might be the reason for prominent FMD  clinical signs in buffalo.
This might also have contributed to more prominent signs in the
non-vaccinated buffalo compared to the non-vaccinated cattle.
However, the dental pad/tongue lesions were less prominent in in-
contact, non-vaccinated, infected buffalo compared to in-contact
non-vaccinated infected cattle. This ﬁnding is in agreement with
earlier studies [5,10,19–21].
In India, it has been observed that FMD  is often overt in cattle
but covert in buffalo, making it difﬁcult to establish the origin and
source of infection. The present study showed that buffalo may  be
infected as readily as cattle and they can also act as a source of infec-
tion for healthy cattle and buffalo upon direct contact, as reported
in the ﬁeld by Gomes et al. [5].
All the vaccinated cattle and four out of six vaccinated buffalo
were protected. However, two  vaccinated buffalo and all the non-
vaccinated cattle and buffalo were clinically affected. The study
indicated that FMD  could be transmitted from infected buffalo to
in-contact non-vaccinated buffalo and cattle. The study also indi-
cated that FMDV transmission could be reduced by vaccinating
buffalo. Although two vaccinated buffalo were clinically infected,
the delayed and low level of non-structural antibody response indi-
cated that there was  less viral replication in these animals than
the unvaccinated in-contact infected animals. Though the challenge
virus is antigenically homologous to vaccine strain, these two vac-
cinated buffalo with 100.9 and 101.1 neutralising antibody response
were not protected whereas a third vaccinated buffalo with simi-
lar range (101.1) of neutralizing antibody response was  protected.
Similar observations were made in cattle previously where the ani-
mals with medium to high neutralising antibody responses were
not able to protect against challenge in contrast to animals with
low neutralising antibody response that were protected [22,23].
Moreover, protection against FMDV infection has been observed in
the absence of a detectable speciﬁc humoral response [24]. Fur-
thermore, it has been recently reported that not only humoral
antibody, but also the cell-mediated immune response have a role
in FMD  vaccine-induced protection [25]. However, in this study
measurement of cell-mediated immune response has not been
characterized. In the present study, serum neutralizing antibody
responses were detected at 14 dpv and peak serum neutralizing
antibody titre were reached at 28 dpv in both vaccinated buf-
falo and cattle. The antibody response elicited by vaccinated and
non-vaccinated buffalo was  comparable with antibody responses
induced in vaccinated and non-vaccinated cattle, respectively. This
M. Madhanmohan et al. / Vaccine 32 (2014) 5125–5130 5129
ct vac
ﬁ
a
N
bFig. 2. Serum neutralising antibody for in-conta
nding is in agreement with our earlier vaccine work (unpublished)
nd also in non-vaccinated cattle and buffalo [5].
There was no essential difference in the detection of FMD
SP antibodies after infection between non-vaccinated cattle and
uffalo. All the vaccinated and non-vaccinated buffalo and cattle
Fig. 3. FMD  NSP antibody response in-contact vacccinated and non-vaccinated buffalo and cattle.
showed NSP antibodies after challenge indicating virus multiplica-
tion in these animals. This clearly indicated that sterile immunity
could not be induced even though the dose of the vaccine was
adequate to offer clinical protection in cattle. Although the titres
of neutralising antibodies were similar for vaccinated cattle and
inated and non-vaccinated buffalo and cattle.
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uffalo, two out of six vaccinated buffalo were clinically infected.
igher payloads of antigen than the usual cattle dose may possibly
onfer protection in buffalo and therefore a dose response study in
uffalo may  be warranted.
In conclusion, the study indicated that FMDV could be transmit-
ed from infected buffalo to susceptible in-contact naïve buffalo and
attle by direct contact. FMD  vaccination of buffalo could reduce
he transmission of disease by reducing virus replication, but for
ompletely blocking the transmission of FMDV, higher doses of
ntigen payload might be required in the vaccine formulation. The
tudy highlights the potential role of Indian buffalo in FMDV trans-
ission, and this is something that may  have an impact on future
ontrol strategy.
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